"FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease" was originally created and published by Pharmaceutical ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.

Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy ... two oral antidepressants. The FDA in 2019 approved Spravato, a close ...

The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for ...

CEO/Founder Nicole Tinson and Senior Vice President of Programs and Partnership Dr. Dennis Johnson, who is a native of Chicago's South Side, joined Jewell Hillery via Zoom on Sunday's WGN Weekend ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ... Spravato administered as a nasal spray achieved a rapid and ...

Payment options are available based on insurance coverage. The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in children aged 4 ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

FDA approves Neffy 1 mg for children aged 4+ weighing 15 to <30 kg for allergic reactions. Most insured patients can access Neffy for $25, while cash price is $199 for two doses. Join Nic Chahine ...